Relação entre infecção urinária e problemas puerperais em porcas.

bitstream/CNPSA/15873/1/publicacao_v2v50v.pd

Effect of tolfenamic acid in postpartum gilts and the performance of their piglets.

Resumo: A síndrome da disgalactia pós-parto (PPDS) é uma doença comum e importante que afeta as matrizes suínas em sistemas intensivos de produção. Na maioria dos casos, a hipogalactia não é claramente identificada, assumindo um aspecto subclínico. Portanto, o presente estudo teve como objetivo avaliar o efeito de um medicamento anti-inflamatório não esteroide (AINE) baseado em ácido tolfenâmico como tratamento profiláctico para PPDS e o desempenho de leitões em aleitamento. As leitoas (n = 319) foram divididas aleatoriamente em dois grupos de tratamento: um grupo de ácido tolfenâmico (n = 157) e um grupo de controle (n = 162). O grupo tratado recebeu uma única injeção intramuscular (1 ml/20 kg de 4% de ácido tolfenâmico) após o parto, enquanto que o grupo de controle não recebeu nenhum tratamento. A ocorrência de PPDS foi então verificada. Todos os leitões (n = 4466) foram pesados com 1, 4, e 18 dias de idade. Todas as leitegadas foram avaliadas quanto ao ganho de peso, ocorrência de diarreia e mortalidade entre os 4 e 18 dias de idade. As variáveis PPDS foram analisadas através de regressão logística. Os pesos de leitões foram analisados com base na covariância, considerando os efeitos do peso inicial e a presença de diarreia. Não houve efeito significativo do ácido tolfenâmico sobre a ocorrência de PPDS. O grupo do ácido tolfenâmico teve menos 0,41% de mortalidade dos leitões até aos 18 dias de idade. O ácido tolfenâmico administrado profilaticamente nas leitoas após o parto reduziu a mortalidade dos leitões durante a lactação e aumentou o ganho de peso nos leitões. Abstract: Postpartum dysgalactia syndrome (PPDS) is a common disorder affecting sows in intensive production systems. In most cases, hypogalactia is not clearly identified and assumes a subclinical aspect. Therefore, the present study aimed to evaluate the effect of a nonsteroidal anti-inflammatory drug (NSAID) based on tolfenamic acid as a prophylactic treatment for PPDS and the performance of suckling piglets. Gilts (n = 319) were randomly divided into two groups: a tolfenamic acid group (n = 157) and a control (n = 162). The tolfenamic acid group received a single intramuscular injection (1 ml/20 kg of 4% tolfenamic acid) after farrowing, whereas the control group received no treatment. The occurrence of PPDS was confirmed. All piglets (n = 4,466) were weighed at 1, 4, and 18 days of age. All litters were evaluated for weight gain, the occurrence of diarrhea, and mortality between 4 and 18 days of age. PPDS variables were analyzed using logistic regression. Piglet weights were analyzed based on covariance while considering the effects of initial weight and the presence of diarrhea. Tolfenamic acid had no significant effect on the incidence of PPDS. The tolfenamic acid group had a 0.41% lower piglet mortality rate until 18 days of age. Tolfenamic acid administered prophylactically to gilts after farrowing reduced piglet mortality during lactation and promoted weight gain

TAT-Mediated Transduction of MafA Protein In Utero Results in Enhanced Pancreatic Insulin Expression and Changes in Islet Morphology

Alongside Pdx1 and Beta2/NeuroD, the transcription factor MafA has been shown to be instrumental in the maintenance of the beta cell phenotype. Indeed, a combination of MafA, Pdx1 and Ngn3 (an upstream regulator of Beta2/NeuroD) was recently reported to lead to the effective reprogramming of acinar cells into insulin-producing beta cells. These experiments set the stage for the development of new strategies to address the impairment of glycemic control in diabetic patients. However, the clinical applicability of reprogramming in this context is deemed to be poor due to the need to use viral vehicles for the delivery of the above factors. Here we describe a recombinant transducible version of the MafA protein (TAT-MafA) that penetrates across cell membranes with an efficiency of 100% and binds to the insulin promoter in vitro. When injected in utero into living mouse embryos, TAT-MafA significantly up-regulates target genes and induces enhanced insulin production as well as cytoarchitectural changes consistent with faster islet maturation. As the latest addition to our armamentarium of transducible proteins (which already includes Pdx1 and Ngn3), the purification and characterization of a functional TAT-MafA protein opens the door to prospective therapeutic uses that circumvent the use of viral delivery. To our knowledge, this is also the first report on the use of protein transduction in utero

Pig-to-Nonhuman Primates Pancreatic Islet Xenotransplantation: An Overview

The therapy of type 1 diabetes is an open challenging problem. The restoration of normoglycemia and insulin independence in immunosuppressed type 1 diabetic recipients of islet allotransplantation has shown the potential of a cell-based diabetes therapy. Even if successful, this approach poses a problem of scarce tissue supply. Xenotransplantation can be the answer to this limited donor availability and, among possible candidate tissues for xenotransplantation, porcine islets are the closest to a future clinical application. Xenotransplantation, with pigs as donors, offers the possibility of using healthy, living, and genetically modified islets from pathogen-free animals available in unlimited number of islets. Several studies in the pig-to-nonhuman primate model demonstrated the feasibility of successful preclinical islet xenotransplantation and have provided insights into the critical events and possible mechanisms of immune recognition and rejection of xenogeneic islet grafts. Particularly promising results in the achievement of prolonged insulin independence were obtained with newly developed, genetically modified pigs islets able to produce immunoregulatory products, using different implantation sites, and new immunotherapeutic strategies. Nonetheless, further efforts are needed to generate additional safety and efficacy data in nonhuman primate models to safely translate these findings into the clinic